How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%.

What other stocks do shareholders of Endocyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD) , Exelixis (EXEL) , Micron Technology (MU) , Rigel Pharmaceuticals (RIGL) , Celldex Therapeutics (CLDX) , NVIDIA (NVDA) , Synergy Pharmaceuticals (SGYP) , Achaogen (AKAO) , Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO) .

NASDAQ:ECYT

Endocyte (ECYT) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free ECYT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $23.99
▼
$23.99
50-Day Range: N/A
52-Week Range: $2.81
▼
$24.00

Volume: N/A
Average Volume: 2.12 million shs
Market Capitalization: $1.97 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Endocyte alerts:

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Endocyte Stock (NASDAQ:ECYT)

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

ECYT Stock News Headlines

February 16, 2024 | investing.com

Telix Pharmaceuticals Ltd (TLX)

January 3, 2024 | fool.com.au

'The most exciting company in Australia': The ASX stock up 179% in 6 months

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

May 17, 2023 | thestreet.com

The Endocyte Bear Thesis: Why March Will be a Bad Month

January 5, 2023 | thestreet.com

Why Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading Today

September 20, 2022 | finance.yahoo.com

Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo Finance

June 6, 2022 | globenewswire.com

Purdue University impacting lives: successfully delivering innovations to the public - GlobeNewswire

May 23, 2022 | globenewswire.com

Global Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswire

April 16, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

May 20, 2022 | benzinga.com

Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Benzinga - Benzinga

May 20, 2022 | streetinsider.com

Cortexyme (CRTX) Appoints Philip Low to Its Board - StreetInsider.com

May 3, 2022 | nasdaq.com

Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? - Nasdaq

April 25, 2022 | seekingalpha.com

Clovis: Shifting Toward Nuclear Medicine - Seeking Alpha

April 14, 2022 | globenewswire.com

Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Research Inc - GlobeNewswire

January 31, 2022 | globenewswire.com

Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight - GlobeNewswire

January 27, 2022 | finance.yahoo.com

Global Oncology Radiopharmaceuticals Market to Surpass US$ 5,206.8 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo Finance

December 19, 2021 | proactiveinvestors.com.au

Radiopharm Theranostics enhances management team skillset with three key appointments - Proactive Investors Australia

November 2, 2021 | finance.yahoo.com

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer - Yahoo Finance

November 2, 2021 | streetinsider.com

Fusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer - StreetInsider.com

September 20, 2021 | streetinsider.com

Mirati Therapeutics (MRTX) Appoints David Meek as CEO - StreetInsider.com

August 16, 2021 | afr.com

Telix Pharma is on the cusp of first US FDA approval - The Australian Financial Review

See More Headlines

Receive ECYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2018
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:ECYT
CUSIP: 29269A10
CIK: 1235007
Web: www.endocyte.com
Phone: 765-463-7175
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.00)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,060,000.00
Net Margins: -32,296.09%
Pretax Margin: N/A
Return on Equity: -21.19%
Return on Assets: -20.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 45.80
Quick Ratio: 45.80

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 28,133.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.99 per share
Price / Book: 12.06

Miscellaneous

Outstanding Shares: 82,090,000
Free Float: N/A
Market Cap: $1.97 billion
Optionable: Optionable
Beta: -0.01

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Michael A. Sherman (Age 52)
CEO, Pres & Director
Mr. Michael T. Andriole (Age 45)
Chief Financial Officer
Dr. Alison A. Armour (Age 54)
Chief Medical Officer
Dr. Christopher P. Leamon (Age 52)
VP of R&D
Dr. Philip S. Low (Age 70)
Co-Founder, Chief Science Officer & Director

Key Competitors

View All Competitors

ECYT Stock Analysis - Frequently Asked Questions

How were Endocyte's earnings last quarter?: Endocyte, Inc. (NASDAQ:ECYT) announced its quarterly earnings data on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%.
What other stocks do shareholders of Endocyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Celldex Therapeutics (CLDX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO).

This page (NASDAQ:ECYT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Endocyte (ECYT) Stock Price, News & Analysis

About Endocyte Stock (NASDAQ:ECYT)

ECYT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ECYT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info